The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
They're taking the GLP1s at at doses that are below the threshold that would give them nausea. So, they're not losing weight quite as quickly. They're not going gaunt quite as quickly. Um, but nonetheless, they're benefiting from I think the appetite suppression, the insulin improved insulin sensitivity, >> inflammation >> and reduced inflammation.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So you're giving them 2.5 milligrams per day, which by the way we are doing in some patients for metabolic for obscure metabolic condition without obesity, right? So we have patients who have um um who have diabetes but are already at very low body weight.
So you're giving them 2.5 milligrams per day, which by the way we are doing in some patients for metabolic for obscure metabolic condition without obesity, right? So we have patients who have um um who have diabetes but are already at very low body weight.